9G DNAChip: microarray based on the multiple interactions of 9 consecutive guanines

Song, Ki-Bong; Nimse, Satish Balasaheb; Kim, Joonbae; Kim, Jung-Hoon; Nguyen, Van-Thuan; Ta, Van-Thao; Kim, Taisun

doi:10.1039/c1cc12489g

Cited by 32 publications

(26 citation statements)

References 25 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before hybridization, the 9G HPV DNA chips were covered with Secure-Seal hybridization chambers. An immobilization density of 6.2 pmol/cm 2 was calculated for the probes immobilized on the HPV 9G DNA chip according to the method in our previous report (17).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

HPV 9G DNA Chip: 100% Clinical Sensitivity and Specificity

Song

Nimse

et al. 2012

J Clin Microbiol

Self Cite

View full text Add to dashboard Cite

We describe a novel HPV 9G DNA chip test for the accurate and reliable genotyping of human papillomavirus (HPV). The HPV 9G DNA chip test established its efficiency in terms of a signal-to-background ratio (SBR) of 200, which is 50 times superior to commercial HPV DNA chips, and 100% target-specific hybridization at 25°C. We compared the genotyping results for the 439 clinical samples by the HPV 9G DNA chip test with the sequencing results for the MY11/GP6؉ (M2) primer set-mediated PCR products. The discrimination of HPV genotypes in the 151 HPV-positive clinical samples by the HPV 9G DNA chip test were 100% identical with the sequencing analysis. The clinical sensitivities of HPV genotyping by the HPV 9G DNA chip test and a commercial HPV DNA chip test were 100% and 88%, respectively. However, the clinical specificities of HPV genotyping by the HPV 9G DNA chip test and the commercial HPV DNA chip test were 100% and 94%, respectively. The 100% clinical sensitivity and specificity of the HPV 9G DNA chip test make it a promising diagnostic tool for HPV genotyping.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Recently reported 9G (GGGGGGGGG) DNA chips based on 9G DNA chip technology show high SBR (PMT gain ϭ 48%) and 100% target-specific hybridization, with more than 90% hybridization efficiency at 25°C in 30 min (17,18 …”

mentioning

confidence: 99%

HPV 9G DNA Chip: 100% Clinical Sensitivity and Specificity

Song

Nimse

et al. 2012

J Clin Microbiol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Among them, 9G DNA chip technology is based on the phenomenon of molecular recognition to immobilize oligonucleotides for the production of DNA chips. The 9G probes are immobilized by multiple interactions of the nine consecutive guanines on the aminomethylcoumarin acetate (AMCA) monolayer [14]. The HPV 9G DNA chip test, which has been approved by the Korea Food and Drug Administration (KFDA), displays a promising diagnostic characteristic of 100% clinical sensitivity and specificity, making it a promising diagnostic tool for HPV genotyping [1518].…”

Section: Discussionmentioning

confidence: 99%

“…HPV 9G DNA genotyping was performed according to the manufacturer's protocol [1415] under the supervision of Dr. A. Lee (a pathologist with a specialty in gynecopathology and molecular pathology). Briefly, all specimens of swabs were placed in a SurePath preservative vial (BD Diagnostics-Tripath BD Biosciences, Oxford, UK) and transferred to the pathology laboratory.…”

Section: Methodsmentioning

confidence: 99%

Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification?

Sung

Lee

et al. 2016

J Gynecol Oncol

View full text Add to dashboard Cite

ObjectiveInfection with high-risk genotypes of human papillomavirus (HR-HPV) is the major cause of invasive cervical cancers. HPV-16 and HPV-18 are known to be responsible for two-thirds of all invasive cervical carcinomas, followed by HPV-45, -31, and -33. Current guidelines only differentiate HPV-16/18 (+) by recommending direct colposcopy for treatment. We tried to evaluate whether there are differences in risk among 12 non-16/18 HR-HPV genotypes in this study.MethodsThe pathology archive database records of 1,102 consecutive gynecologic patients, who had results for cervical cytology and histology and for HPV testing, as determined by HPV 9G DNA chip, were reviewed.ResultsAmong the 1,102 patients, 346 were non-16/18 HR-HPV (+) and 231 were HPV-16/18 (+). We calculated the odds ratios for ≥cervical intraepithelial neoplasia 2 (CIN 2) of 14 groups of each HR-HPV genotype compared with a group of HR-HPV (–) patients. Based on the odds ratio of each genotype, we divided patients with non-16/18 HR-HPV genotypes (+) into two groups: HPV-31/33/35/45/52/58 (+) and HPV-39/51/56/59/66/68 (+). The age-adjusted odds ratios for ≥CIN 2 of the HPV-31/33/35/45/52/58 (+) and HPV-39/51/56/59/66/68 (+) groups compared with a HR-HPV (–) group were 11.9 (95% CI, 7.6 to 18.8; p<0.001) and 2.4 (95% CI, 1.4 to 4.3; p<0.001), respectively, while that of the HPV-16/18 (+) group was 18.1 (95% CI, 11.6 to 28.3; p=0.003).ConclusionThe 12 non-16/18 HR-HPV genotypes can be further categorized (HPV-31/33/35/45/52/58 vs. HPV-39/51/56/59/66/68) by risk stratification. The HPV-31/33/35/45/52/58 genotypes might need more aggressive action. Large scale clinical trials or cohort studies are necessary to confirm our suggestion.

show abstract

“…The MTB-DR-RIF 9G test is a new diagnostic tool based on the recently reported 9G technology [20], and the controller DNA technology (CDT) [21]. The MTB-DR-RIF 9G test can discriminate multiple SNPs in the five codons (c511, c516, c522, c526, and c531) of MTB strains at 25 C, in less than 30 min after PCR.…”

Section: Introductionmentioning

confidence: 99%